Research programme: immunological disorders therapy - Immune Control/Provid Pharmaceuticals
Latest Information Update: 04 Apr 2008
At a glance
- Originator Immune Control; Provid Pharmaceuticals
- Mechanism of Action Serotonin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 06 Jul 2005 Early research in Immunological disorders in USA (unspecified route)